RHEACELL

About RHEACELL

With late-stage data available for CVU and an ongoing pivotal phase 3 trial for RDEB, RHEACELL is a leading biopharmaceutical company that is dedicated to developing innovative therapies for patients suffering from severe inflammation driven diseases, such as RDEB and therapy resistant non-healing chronic venous ulcers based on our proprietary ABCB5+mesenchymal stromal cells (MSCs) platform technology - exclusively licensed by RHEACELL from Children´s Medical Center (CMCC), Harvard Medical School. Our mission is to provide a new and innovative standard of care for patients who currently have no satisfactory treatment options. We believe that our therapy can make a real difference for the lives of these patients. Our innovative proprietary cell therapy with ABCB5+ MSCs for the treatment of non-healing chronic venous wounds has already been granted with a national market approval for external/topical use in CVU patients, by the Paul-Ehrlich-Institute in Germany in 2021 (AMESANAR®). The cell therapy targets inflammation and is enabling recovery of normal physiological function and initiating neo-vascularization after topical application. With late-stage data available, our CVU phase-2b clinical trial across Germany is ongoing. With RDEB -orphan & rare-, "the worst disease you have never heard of", we are in a pivotal phase 3 clinical trials in Europe and the US with EBESANAR®. With our unique product characteristics, mode of action and the systemic (intra-venous) approach, our cells are first in class and best in class by targeting external and internal wounds, leading to a reduction of overall disease burden in patients by significant reduction of wounds, enabling recovery of normal physiological function of the affected tissue and preventing the formation of new wounds. We are specialists in clinical development and have full control over the entire workflow from bench to bedside, from pre-clinical development to a pivotal phase 3 trial and beyond.

View contact profiles from RHEACELL